We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Currently, six CART-cell immunotherapies have been approved in China and abroad, as shown in the table below. Except for Abecma, the other five therapies are all targeted at CD19.